Wednesday, 18 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

7:31 AM ET 8-K
Financial Results Nextdoor Holdings, Inc. NXDR

Nextdoor Holdings Financial Results

Nextdoor Holdings reported Q3 2026 financial results with revenue of $78.8 million, up 14% year-over-year, and a significantly narrowed net loss of less than $1 million. The company achieved its third consecutive quarter of sequential Platform Weekly Active User (WAU) growth, reaching 24.5 million users.

Term
Q3 2026

“Q3 was another record quarter for Nextdoor, and the strongest proof yet that our transformation is well underway. Platform WAU grew for the third straight quarter to 24.5 million, revenue grew 14%, and our net loss narrowed to less than $1 million from $13 million a year ago. This progress comes from hundreds of improvements that compound on one another, and from a team that kept building long before the numbers confirmed it. In a world where more of the internet is becoming synthetic, what becomes scarce is real people, verified to a real place, helping one another. We’re carrying this momentum into the fourth quarter and beyond.”

Nirav Tolia, Nextdoor CEO and Co-Founder

“Q3 was a strong quarter of steady progress, with Adjusted EBITDA above our guidance range and Adjusted EBITDA margin up 7 points from a year ago. Our fourth quarter outlook puts full-year revenue growth in line with the low-teens range we provided last quarter. And with $28 million of operating cash flow so far this year, we’re able to keep investing in the business while opportunistically returning capital to shareholders through our buyback.”

Indrajit Ponnambalam, Nextdoor CFO
7:26 AM ET 10-Q
Financial Results Dyne Therapeutics, Inc. DYN

Dyne Therapeutics Q3 2026 Results: Net Loss of $194M, Loss Widens

Dyne Therapeutics, Inc. is a clinical-stage biotechnology company focused on muscle diseases using its proprietary FORCE platform. As of October 30, 2026, the company had 187,386,963 shares of common stock outstanding and expects to require substantial additional funding to advance its product candidates, which are not anticipated to reach commercialization until at least 2027.

Key figure
Net loss $194M
7:25 AM ET 10-Q
Financial Results C4 Therapeutics, Inc. CCCC

C4 Therapeutics Q3 2026 Results: Net Loss of $21.8M, Loss Narrows

C4 Therapeutics is a clinical-stage biopharmaceutical company focused on its TORPEDO platform and protein degrader candidates. As of October 30, 2026, the company had 131,317,488 shares of common stock outstanding and continues to incur significant losses to fund its research and development programs.

Key figure
Net loss $21.8M
7:25 AM ET 10-Q
Financial Results Conocophillips COP ▶ Call

Conocophillips Q3 2026 Results: Net Income $4B, Up 131.8% YoY

ConocoPhillips reported a significant increase in net income for the third quarter of 2026, reaching $4,001 million compared to $1,726 million in the same period of 2025. This growth was driven by higher sales and operating revenues, which rose to $19.4 billion for the quarter, while the company continued its shareholder return program through $5.4 billion in stock repurchases year-to-date.

Key figure
Net income $4B · +131.8% YoY
7:24 AM ET 10-Q
Financial Results Latigo Biotherapeutics, Inc. LTGO

Latigo Biotherapeutics Q3 2026 Results: Net Loss of $20.9M, Loss Narrows

Latigo Biotherapeutics is a clinical-stage biopharmaceutical company that has incurred an accumulated deficit of $312.8 million as of September 30, 2026. The company is focused on developing its lead product candidates, onzotrigine and LTG-321, and anticipates continued substantial losses as it funds research and development.

Key figure
Net loss $20.9M
7:23 AM ET 8-K
Financial Results Cogent Communications Holdings, Inc. CCOI

Cogent Communications Holdings Financial Results

Cogent Communications reported Q3 2026 service revenue of $231.2 million, a 1.8% sequential decrease, while Adjusted EBITDA rose 3.9% to $73.9 million. The company highlighted strong growth in wavelength revenue, which increased 57% year-over-year, and announced non-binding letters of intent to sell four data centers for approximately $100 million.

Term
Q3 2026

“On November 5, 2026, Cogent Communications Holdings, Inc. issued a press release summarizing its financial results for the third quarter of 2026.”

David Schaeffer, President and Chief Executive Officer
7:21 AM ET 10-Q
Financial Results Regenxbio Inc. RGNX

Regenxbio Q3 2026 Results: Net Loss of $40.7M, Loss Narrows

REGENXBIO Inc. reported total assets of $466.0 million as of September 30, 2026, with a significant increase in cash and cash equivalents to $95.8 million compared to $34.5 million at year-end 2025. The company is currently managing clinical holds on its RGX-121 and RGX-111 programs while continuing development partnerships with AbbVie and Nippon Shinyaku.

Key figure
Net loss $40.7M
7:21 AM ET 10-Q
Financial Results Vistance Networks, Inc. VISN

Vistance Networks Q3 2026 Results: Net Income $1.03B, Up 850.7% YoY

Vistance Networks reported a significant increase in net income to $6,833.7 million for the nine months ended September 30, 2026, primarily driven by a $6,736.3 million gain from discontinued operations. During the period, the company completed major divestitures resulting in $12.4 billion in net proceeds, which were used to repay $7.37 billion in long-term debt and fund $3.44 billion in special distributions to common stockholders.

Key figure
Net income $1.03B · +850.7% YoY
7:20 AM ET 8-K
M&A Deal Black Spade Acquisition III Co BIII

Black Spade Acquisition III M&A Deal with Astrum Space Inc

Black Spade Acquisition III Co entered into a first amendment to its existing business combination agreement with Astrum Space Inc. The amendment updates the terms to allow the surviving company to list on either the NYSE or Nasdaq, as mutually agreed upon by both parties. This filing provides a status update on the pending merger between the SPAC and the satellite-to-device network company.

Counterparty
Astrum Space Inc
7:20 AM ET 10-Q
Financial Results Verisk Analytics, Inc. VRSK ▶ Call

Verisk Analytics Q3 2026 Results: Net Income $219M, Down 2.8% YoY

Verisk Analytics reported Q3 2026 revenues of $544.0 million, with net income attributable to Verisk of $128.2 million. The company maintained a strong liquidity position with a $2.0 billion syndicated revolving credit facility and reported diluted earnings per share of $3.0 for the quarter.

Key figure
Net income $219M · -2.8% YoY
7:20 AM ET 10-Q
Financial Results Zenas BioPharma, Inc. ZBIO

Zenas BioPharma Q3 2026 Results: Net Loss of $109M, Loss Widens

Zenas BioPharma, Inc. reported a significant increase in liquidity as of September 30, 2026, with cash, cash equivalents, and short-term investments totaling approximately $585.3 million, up from $343.2 million at the end of 2025. The company continues to operate as a non-accelerated filer and emerging growth company, focusing on the development of product candidates for immunology and inflammation diseases.

Key figure
Net loss $109M
7:20 AM ET 10-Q
Financial Results Certara, Inc. CERT

Certara Q3 2026 Results: Net Income $5.59M, Up 266.7% YoY

Certara reported third-quarter 2026 revenues of $94.9 million, a 4.4% increase year-over-year, and net income of $5.6 million. However, for the nine months ended September 30, 2026, the company recorded a net loss of $58.4 million, primarily driven by a significant $37.0 million loss from discontinued operations.

Key figure
Net income $5.59M · +266.7% YoY
7:18 AM ET 8-K
Financial Results Lincoln International, Inc. LCLN

Lincoln International Financial Results

Lincoln International reported record third-quarter 2026 revenue of $293.7 million, a 57% increase year-over-year, driven by strong growth in Investment Banking Advisory and the acquisition of MarshBerry. The company achieved GAAP net income of $9.9 million ($0.25 per diluted share) and adjusted net income of $50.2 million ($0.46 per adjusted diluted share).

Term
Q3 2026

“Lincoln delivered a record third quarter, achieving new highs in both revenue and adjusted earnings, with strong growth across our Investment Banking Advisory and Valuations and Opinions businesses. We are entering the fourth quarter from a position of strength, supported by healthy pipeline activity and continued client engagement. Looking ahead, we remain focused on executing our long-term strategy through continued investment in our people, technology and global platform to further strengthen our competitive position and drive sustainable growth.”

Rob Brown, Chief Executive Officer of Lincoln International
7:18 AM ET 8-K
Financial Results TIC Solutions, Inc. TIC

TIC Solutions Financial Results

TIC Solutions reported record third quarter 2026 revenue of $639.6 million, a 35% increase year-over-year primarily driven by the acquisition of NV5. Despite a net loss of $11.1 million, the company achieved record combined backlog of $1.29 billion and increased its full-year 2026 revenue outlook.

Term
Q3 2026

“We delivered a record third quarter. On a combined basis, revenue grew 12.5%, including organic growth of 8.4%, Adjusted EBITDA grew 19%, and Adjusted EBITDA margin expanded approximately 90 basis points to 16.8%.”

Ben Heraud, CEO of TiC Solutions

“This quarter’s results reinforce the strategic rationale of bringing Acuren and NV5 together. Our recent acquisitions add complementary capabilities and client relationships that broaden our growth opportunities in strategic end markets, service lines, and geographies.”

Robert A.E. Franklin, Executive Chairman of TiC Solutions
7:17 AM ET 8-K
Other 8-K Filing Wendy's Co WEN

Wendy's Other 8-K Filing

The Wendy's Company adopted a stockholder rights plan (poison pill) in response to an unsolicited $7.35 per share acquisition proposal from an investor group led by Trian Fund Management. The Board's independent committee rejected the proposal, concluding it substantially undervalues the company's long-term prospects and its new strategic plan, 'Dave's Way'.

Counterparty
Trian Fund Management, L.P.
7:17 AM ET 8-K
Financial Results Verisk Analytics, Inc. VRSK

Verisk Analytics Financial Results

Verisk Analytics reported third quarter 2026 financial results with revenue of $809 million, up 5.3% year-over-year, and diluted adjusted EPS of $1.96. The company highlighted strong subscription growth of 8.2% and reaffirmed its full-year 2026 guidance targets.

Term
Q3 2026

“Our strong third-quarter results underscore the resilience of our subscription-based business model and the mission-critical role Verisk plays in the insurance ecosystem. We are executing with discipline against our strategic priorities by deepening client partnerships, accelerating AI-powered innovation at scale, and expanding the network effects that connect participants and enhance value across the insurance value chain.”

Lee Shavel, President and CEO

“I'm pleased to share that Verisk delivered third-quarter financial results that returned to levels in line with our annual Investor Day targets and reflect the continued sequential acceleration in growth we previously articulated. In third-quarter 2026, OCC revenue increased 7.4% with strong subscription growth of 8.2% and transactional growth of 3.2%.”

Elizabeth Mann, CFO
7:17 AM ET 8-K
Financial Results Shutterstock, Inc. SSTK

Shutterstock Financial Results

Shutterstock reported Q3 2026 revenue of $173.9 million, a 33% year-over-year decrease driven by weakness in new customer acquisition and data licensing timing. The company recorded a net loss of $197.8 million, which included a $195.6 million non-cash goodwill impairment charge. Additionally, the company announced the appointment of Scott Grossman as Interim CFO, succeeding Rik Powell.

Term
Q3 2026

“During the third quarter, we maintained a strong focus on operational discipline and cost management while navigating continued headwinds in our core Content segment and deal timing volatility in Data Licensing.”

Jon Oringer, Chairman and Chief Executive Officer

“We reduced third-quarter Product Development and SG&A expenses by 30% year-over-year to $96 million, representing $39 million in quarterly savings, while reducing total headcount by 16% year-to-date.”

Jon Oringer, Chairman and Chief Executive Officer
7:17 AM ET 8-K
Loan & Debt Dream Finders Homes, Inc. DFH

Dream Finders Homes $650M Debt Financing with Beazer Homes USA, Inc.

Dream Finders Homes announced the early participation results of its private exchange offers for $650 million in outstanding senior notes previously issued by its newly acquired subsidiary, Beazer Homes USA. As of the early deadline, over 98% of the 7.500% notes due 2031 and 8.000% notes due 2032 had been tendered for new Dream Finders notes, providing the requisite consents to strip restrictive covenants from the original Beazer indentures.

Value
$650M
Counterparty
Beazer Homes USA, Inc.
7:17 AM ET 10-Q
Financial Results Centrus Energy Corp LEU

Centrus Energy Q3 2026 Results: Net Income $31.6M, Up 710.3% YoY

Centrus Energy Corp. reported its third-quarter 2026 results, highlighting its transition toward domestic HALEU and LEU production under multiple IDIQ contracts with the DOE. The company is navigating geopolitical risks including the Russian Uranium Import Ban and the Russian Decree rescinding TENEX's export license, while planning significant capacity expansions in Piketon, Ohio.

Key figure
Net income $31.6M · +710.3% YoY
7:17 AM ET 10-Q
Financial Results McGraw Hill, Inc. MH ▶ Call

McGraw Hill Q2 2026 Results: Net Income $86.4M, Down 18.0% YoY

For the six months ended September 30, 2026, McGraw Hill reported revenue of $1.18 billion and net income of $144.2 million, an increase from $105.8 million in the prior year period. The company highlighted risks related to technological developments in artificial intelligence and potential shifts in U.S. Department of Education funding and policy.

Key figure
Net income $86.4M · -18.0% YoY
7:16 AM ET 8-K
Financial Results Aclaris Therapeutics, Inc. ACRS

Aclaris Therapeutics Financial Results

Aclaris Therapeutics reported its Q3 2026 financial results, highlighting a cash position of $156.4M which is expected to fund operations through the first half of 2029. The company also provided clinical updates, including positive Phase 1b data for ATI-052 in atopic dermatitis and asthma, and the planned initiation of a Phase 2b trial for modzatinib in the fourth quarter of 2026.

Term
Q3 2026

“Aclaris is developing unique product candidates designed to provide improved therapeutic options across a variety of inflammatory disorders with the goal of raising the efficacy ceiling, and our recent progress reflects continued execution toward that objective.”

Dr. Neal Walker, Chief Executive Officer and Chair of the Board of Directors of Aclaris
7:16 AM ET 8-K
Financial Results C4 Therapeutics, Inc. CCCC

C4 Therapeutics Financial Results

C4 Therapeutics reported financial results for the third quarter of 2026, highlighting clinical progress for its lead candidate cemsidomide. The company remains on track to complete enrollment for the Phase 2 MOMENTUM trial in Q1 2027 and expects initial data from multiple combination cohorts in mid-to-late 2027.

“Throughout the year, we have continued to build evidence supporting cemsidomide’s potential as a backbone therapy across the multiple myeloma treatment landscape while advancing our clinical development plan to evaluate cemsidomide in late and earlier lines of therapy.”

Andrew Hirsch, president and chief executive officer of C4 Therapeutics

“With data expected from these trials in 2027, we believe next year will be pivotal in establishing cemsidomide’s therapeutic profile and its potential to address the significant unmet need of patients with multiple myeloma across an evolving standard of care.”

Andrew Hirsch, president and chief executive officer of C4 Therapeutics
7:16 AM ET 8-K/A
Divestiture TripAdvisor, Inc. TRIP

TripAdvisor Divestiture to American Express Travel Related Services Company, Inc. for $700M

Tripadvisor completed the sale of its European online restaurant reservation platform, TheFork, to American Express Travel Related Services Company for $700 million in cash. The transaction closed on November 1, 2026, following the receipt of required regulatory approvals and completion of employee consultation processes. This filing provides the required pro forma financial information reflecting the business as a discontinued operation.

Value
$700M
Counterparty
American Express Travel Related Services Company, Inc.
7:14 AM ET 8-K
Financial Results McGraw Hill, Inc. MH

McGraw Hill Financial Results

McGraw Hill reported fiscal second quarter 2027 results with revenue of $632.2 million, exceeding expectations despite a 5.5% year-over-year decline. The company highlighted growth in digital revenue and an agentic AI strategy connecting proprietary content to platforms like Microsoft Copilot and Anthropic’s Claude.

Term
Fiscal Q2 2027

“McGraw Hill's first half fiscal year 2027 performance underscores our continued higher education market share gains, scale and deep position of trust serving over 100 million active curriculum licenses across the global education ecosystem.”

Philip Moyer, President, Chief Executive Officer

“Our second quarter results demonstrated digital revenue growth, a strong margin profile and commitment to gross debt reduction. Our first-half performance, including robust re-occurring revenue growth, combined with strengthening indicators of our ability to deliver accelerating growth in fiscal year 2028, reinforces our confidence in our long-term strategy.”

Bob Sallmann, Executive Vice President, Chief Financial Officer
7:14 AM ET 10-Q
Financial Results TIC Solutions, Inc. TIC

TIC Solutions Q3 2026 Results: Net Loss of $11.1M, Loss Narrows

TIC Solutions, Inc. reported a net loss of $11.1 million for the third quarter of 2026, despite a significant revenue increase to $639.6 million compared to $473.9 million in the prior year period. The company's financial position was impacted by higher operating expenses and interest costs, while total assets remained stable at approximately $4.4 billion.

Key figure
Net loss $11.1M
7:14 AM ET 8-K
Financial Results Kimbell Royalty Partners, LP KRP

Kimbell Royalty Partners Financial Results

Kimbell Royalty Partners reported record Q3 2026 daily production of 27,565 Boe/d and consolidated Adjusted EBITDA of $80.4 million. The company also announced a quarterly cash distribution of $0.45 per unit and increased its revolving credit facility borrowing base to $750 million.

Term
Q3 2026

“We are pleased to report record third quarter results, which were driven by strong organic growth and the partial contribution from our recent $221.2 million Drop Down acquisition.”

Robert Ravnaas, Chairman and Chief Executive Officer
7:14 AM ET 10-Q
Financial Results WW International, Inc. WW

WW International Q3 2026 Results: Turns Profitable, Net Income $15.1M

WW International reported a net income of $15.1 million for the quarter ended September 30, 2026, a significant recovery from a $57.5 million loss in the prior year period. However, for the nine months ended September 30, 2026, the company recorded a net loss of $22.8 million as subscription revenues declined from $170.9 million to $152.0 million year-over-year.

Key figure
Net income $15.1M
7:14 AM ET 8-K
Financial Results Akebia Therapeutics, Inc. AKBA

Akebia Therapeutics Financial Results

Akebia Therapeutics reported Q3 2026 financial results, highlighted by a 140% year-over-year increase in patients on Vafseo to approximately 11,500. The company reported Vafseo net product revenues of $14.8 million and maintained a strong cash position of $159.3 million as it prepares for expanded market access in 2027.

Term
Q3 2026

“Our strategic commercial priority remains making Vafseo standard of care for the treatment of anemia for patients on dialysis, and we are focused on continuing to increase the number of patients on therapy.”

John P. Butler, Chief Executive Officer of Akebia

“We believe this compelling data has the potential to drive Vafseo to be standard of care. We continue to work to strengthen our market position as we enter 2027 when we believe Vafseo access will expand beyond the Transitional Drug Add-on Payment Adjustment (TDAPA)-only patients to nearly all clinically eligible patients.”

John P. Butler, Chief Executive Officer of Akebia
7:14 AM ET 8-K
Financial Results Appian Corp APPN

Appian Financial Results

Appian Corp reported third quarter 2026 financial results with total revenue increasing 25% year-over-year to $234.6 million, driven by a 20% rise in cloud subscriptions revenue. The company achieved GAAP net income of $12.3 million ($0.17 per diluted share) and provided full-year 2026 revenue guidance of $873 million to $877 million.

Term
Q3 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.